Daewoong Pharmaceutical Co Ltd (Daewoong Pharmaceutical), a subsidiary of Daewoong Co Ltd, focuses on the research, development, manufacturing and commercialization of pharmaceuticals. The company offers a broad portfolio of prescription drugs and non-prescription products for various conditions including bone and joint diseases, cardiovascular diseases, central nervous system diseases, diabetes, circulatory system, dermatological, gastrointestinal, health supplements and respiratory remedies, among others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Daewoong Pharmaceuticals conducts R&D to discover new drugs, biologics and new products for cancer, immune diseases, stem cell therapy for intractable and rare diseases, and vaccines. It also in-licenses various products from other companies and develops them. In FY2022, the company incurred KRW163,601.6 million on R&D activities, which as a percentage of revenue, stood at 12.7% and recorded growth of 28.5% during FY2022. The company strives to provide the best drugs and biologics. It concentrates on pipeline products and collaborates with other organizations to enter new markets. The company continues to work on the development of fibrosis, autoimmune, and cancer treatments. Daewoong Pharmaceuticals sells its botulinum toxin product, Nabota, in the US the under trade name Jeuveau. The company develops cell therapy as CMO and CDMO in Biologics.